{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:33:46Z","timestamp":1791110026277,"version":"4.1.0"},"reference-count":110,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Can J Psychiatry"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the different pharmacological approaches to the cognitive, functional, and behavioural manifestations of Alzheimer disease (AD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We searched and critically analyzed the most recent relevant literature on pharmacological treatment of AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The current pharmacological approach to AD treatment is based on vascular prevention and symptomatic therapy with cholinesterase inhibitors (ChEIs) and memantine, an N-methyl-d-aspartic acid antagonist. Clinical trials of 6\u2013 to 12\u2013month duration have shown statistically significant benefits with ChEIs and memantine on cognitive, global, functional, and behavioural outcome measures. In general, these benefits are modest. However, they are dose-dependent and reproducible across studies. Most importantly, these benefits are symptomatic as they do not alter disease course. According to the third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, these agents are considered standard treatment options in AD. We will discuss practical issues related to current pharmacological management, such as setting realistic expectations, management of side effects, switching ChEIs, and the decision to discontinue treatment. The results of clinical trials studying potentially disease-modifying approaches in AD will also be reviewed. Unfortunately, although there remains much promise and enthusiasm, none of these agents has shown consistent benefits, and none are available for use in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Pharmacological options are presently available for the symptomatic treatment of AD. These treatments provide mild but sustained benefits. Before disease-modifying approaches become available, optimizing the use of the available treatment options is crucial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/070674371105601003","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T07:44:21Z","timestamp":1484120661000},"page":"579-588","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":97,"title":["Pharmacological Treatment of Alzheimer Disease"],"prefix":"10.1177","volume":"56","author":[{"given":"Fadi","family":"Massoud","sequence":"first","affiliation":[{"name":"Internist-Geriatrician, Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al, H\u00f4pital Notre-Dame, Montreal, Quebec; Associate Professor of Medicine, Department of Medicine, University of Montreal, H\u00f4pital Notre-Dame, Service de G\u00e9riatrie, Montreal, Quebec"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel C","family":"L\u00e9ger","sequence":"additional","affiliation":[{"name":"Neurologist, Neurology Service, Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al, H\u00f4pital Notre-Dame, Montreal, Quebec; Clinical Assistant Professor and Director, Neurology Program, Universit\u00e9 de Montr\u00e9al, H\u00f4pital Notre-Dame, Service de Neurologie, Montreal, Quebec"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2011,10,1]]},"reference":[{"key":"bibr1-070674371105601003","volume-title":"World Alzheimer report 2009 [Internet]","author":"Alzheimer's Disease International","year":"2009"},{"key":"bibr2-070674371105601003","volume-title":"World Alzheimer report 2010 [Internet]","author":"Alzheimer's Disease International","year":"2010"},{"key":"bibr3-070674371105601003","volume-title":"Rising tide: The impact of dementia on Canadian society [Internet]","author":"Alzheimer Society","year":"2010"},{"key":"bibr4-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0909142"},{"key":"bibr5-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.2001.81.2.741"},{"key":"bibr6-070674371105601003","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-8-200404200-00047"},{"key":"bibr7-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040223"},{"key":"bibr8-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4886(95)90041-1"},{"key":"bibr9-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.12-02-00376.1992"},{"key":"bibr10-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.66.2.137"},{"key":"bibr11-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65184-X"},{"key":"bibr12-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M"},{"key":"bibr13-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(93)90078-Z"},{"key":"bibr14-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/0959-4388(95)80073-5"},{"key":"bibr15-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.9.15.8529836"},{"key":"bibr16-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70537-3"},{"key":"bibr17-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540340047031"},{"key":"bibr18-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe0901965"},{"key":"bibr19-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806142"},{"key":"bibr20-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21413"},{"key":"bibr21-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03086-4"},{"key":"bibr22-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(99)00156-9"},{"key":"bibr23-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.9.1069"},{"key":"bibr24-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801369"},{"key":"bibr25-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70143-1"},{"key":"bibr26-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2007.07.009"},{"key":"bibr27-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15690-0"},{"key":"bibr28-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11600-X"},{"key":"bibr29-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181b59bf3"},{"key":"bibr30-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1126\/science.7058341"},{"key":"bibr31-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp176"},{"key":"bibr32-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.7.1011"},{"key":"bibr33-070674371105601003","doi-asserted-by":"crossref","unstructured":"Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2006:CD001190.","DOI":"10.1002\/14651858.CD001190.pub2"},{"key":"bibr34-070674371105601003","doi-asserted-by":"publisher","DOI":"10.2147\/ciia.2007.2.1.17"},{"key":"bibr35-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1035"},{"key":"bibr36-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000281848.25142.11"},{"key":"bibr37-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000281847.17519.e0"},{"key":"bibr38-070674371105601003","doi-asserted-by":"crossref","unstructured":"Birks J, Evans J Grimley, Iakovidou V, Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2009:CD001191.","DOI":"10.1002\/14651858.CD001191.pub2"},{"key":"bibr39-070674371105601003","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200623100-00006"},{"key":"bibr40-070674371105601003","doi-asserted-by":"crossref","unstructured":"Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006:CD001747.","DOI":"10.1002\/14651858.CD001747.pub3"},{"key":"bibr41-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08267-3"},{"key":"bibr42-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1517\/14740330802528420"},{"key":"bibr43-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(96)80008-3"},{"key":"bibr44-070674371105601003","doi-asserted-by":"crossref","unstructured":"McShane R, Sastre A Areosa, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006:CD003154.","DOI":"10.1002\/14651858.CD003154.pub5"},{"key":"bibr45-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.3.317"},{"key":"bibr46-070674371105601003","doi-asserted-by":"publisher","DOI":"10.2174\/157015910790909520"},{"key":"bibr47-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1177\/0269881106068299"},{"key":"bibr48-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.9.1154"},{"key":"bibr49-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2006.10.001"},{"key":"bibr50-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2007.07.006"},{"key":"bibr51-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1097\/01.JGP.0000221334.65330.55"},{"key":"bibr52-070674371105601003","volume-title":"Alzheimer's disease\u2014donepezil, rivastigmine, galantamine and memantine (review)\u2014final appraisal [Internet]","author":"National Institute for Health and Clinical Excellence (NICE)","year":"2011"},{"key":"bibr53-070674371105601003","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-5-200803040-00008"},{"key":"bibr54-070674371105601003","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-5-200803040-00009"},{"key":"bibr55-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610210001985"},{"key":"bibr56-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(91)90052-2"},{"key":"bibr57-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70119-8"},{"key":"bibr58-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2009.05.177"},{"key":"bibr59-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2008.05.003"},{"key":"bibr60-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0503839103"},{"key":"bibr61-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20050560"},{"key":"bibr62-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500369"},{"key":"bibr63-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2009.05.219"},{"key":"bibr64-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1586\/ern.09.24"},{"key":"bibr65-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903044982"},{"key":"bibr66-070674371105601003","volume-title":"Lilly halts development of semagacestat for Alzheimer's disease based on preliminary results of phase III clinical trials [Internet]","author":"Eli Lilly","year":"2010"},{"key":"bibr67-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2005.06.030"},{"key":"bibr68-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1172\/JCI18162"},{"key":"bibr69-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70090-5"},{"key":"bibr70-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1866"},{"key":"bibr71-070674371105601003","doi-asserted-by":"publisher","DOI":"10.2174\/0929867023370121"},{"key":"bibr72-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2009.04.925"},{"key":"bibr73-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2101"},{"key":"bibr74-070674371105601003","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2009-1044"},{"key":"bibr75-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000244346.08950.64"},{"key":"bibr76-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2009.06.003"},{"key":"bibr77-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-009-0106-x"},{"key":"bibr78-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-2-17"},{"key":"bibr79-070674371105601003","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2006-102-303"},{"key":"bibr80-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2008.06.018"},{"key":"bibr81-070674371105601003","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-1390"},{"key":"bibr82-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70167-4"},{"key":"bibr83-070674371105601003","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2008-15207"},{"key":"bibr84-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-007-0156-7"},{"key":"bibr85-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.033399"},{"key":"bibr86-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2007.12.021"},{"key":"bibr87-070674371105601003","doi-asserted-by":"publisher","DOI":"10.2165\/11533070-000000000-00000"},{"key":"bibr88-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000159740.16984.3C"},{"key":"bibr89-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000073623.84147.A8"},{"key":"bibr90-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1038\/nm840"},{"key":"bibr91-070674371105601003","doi-asserted-by":"publisher","DOI":"10.2174\/156720509787602852"},{"key":"bibr92-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61075-2"},{"key":"bibr93-070674371105601003","doi-asserted-by":"publisher","DOI":"10.4161\/hv.6.11.12655"},{"key":"bibr94-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61316-5"},{"key":"bibr95-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2009.06181.x"},{"key":"bibr96-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(00)02031-2"},{"key":"bibr97-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1007\/BF00308809"},{"key":"bibr98-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000063311.58879.01"},{"key":"bibr99-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(99)00063-9"},{"key":"bibr100-070674371105601003","first-page":"21","volume":"6","author":"Nagy Z","year":"1995","journal-title":"Dementia"},{"key":"bibr101-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0b013e328314b78b"},{"key":"bibr102-070674371105601003","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09com05331"},{"key":"bibr103-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3203-08.2008"},{"key":"bibr104-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-9610com"},{"key":"bibr105-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2007.12.002"},{"key":"bibr106-070674371105601003","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2009-1095"},{"key":"bibr107-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61074-0"},{"key":"bibr108-070674371105601003","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2008-15213"},{"key":"bibr109-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2008.12.015"},{"key":"bibr110-070674371105601003","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4305-10.2010"}],"container-title":["The Canadian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/070674371105601003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/070674371105601003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:12:57Z","timestamp":1777392777000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/070674371105601003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":110,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1177\/070674371105601003"],"URL":"https:\/\/doi.org\/10.1177\/070674371105601003","relation":{},"ISSN":["0706-7437","1497-0015"],"issn-type":[{"value":"0706-7437","type":"print"},{"value":"1497-0015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}